Gilead Sciences, Inc. (GILD)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Gilead Sciences, Inc. (GILD) trades at $131.27 with AI Score 94/100 (Grade A+). Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs. Market cap: $162.98B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026GILD stock analysis for 2026: Analysts have set a consensus price target of $155.41 for Gilead Sciences, Inc., suggesting 18.4% upside from the current price of $131.27. The AI MoonshotScore is 94/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
GILD: 5/7 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Gilead Sciences, Inc. (GILD) Healthcare & Pipeline Overview
Gilead Sciences, Inc. pioneers antiviral therapies, holding a dominant position in HIV/AIDS treatment and expanding into oncology and liver diseases. With a robust pipeline and strategic collaborations, Gilead addresses critical unmet medical needs globally, while facing patent expirations and competition from major pharmaceutical players.
What Is the Investment Thesis for GILD?
Gilead Sciences, Inc. presents a compelling investment case based on its established dominance in HIV treatment, expanding oncology portfolio, and strategic collaborations. With a P/E ratio of 16.9 and a profit margin of 31.0%, Gilead demonstrates financial stability. Growth catalysts include pipeline advancements in oncology and continued revenue from HIV therapies. A dividend yield of 2.43% offers income potential. However, potential risks include patent expirations on key drugs and competition from other pharmaceutical companies. Investors should monitor the progress of Gilead's pipeline and its ability to maintain market share in key therapeutic areas.
Based on FMP financials and quantitative analysis
GILD Key Highlights
- Market Cap of $162.98B reflects Gilead's significant presence in the biopharmaceutical industry.
- P/E Ratio of 16.9 indicates a potentially reasonable valuation compared to earnings.
- Profit Margin of 31.0% highlights Gilead's efficiency in converting revenue into profit.
- Gross Margin of 79.4% demonstrates strong pricing power and cost management in its product portfolio.
- Dividend Yield of 2.43% provides an income stream for investors, supported by Gilead's cash flow.
Who Are GILD's Competitors?
GILD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRK Merck & Co., Inc. | $129.52 | +3.31% | $319.89B | 83 |
| AMGN Amgen Inc. | $374.15 | +3.55% | $201.93B | 83 |
| NVO Novo Nordisk A/S | $50.43 | +3.40% | $224.10B | 51 |
| PFE Pfizer Inc. | $24.32 | +1.84% | $138.61B | 64 |
| DHR Danaher Corporation | $197.93 | +2.17% | $140.09B | 69 |
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
| AZN AstraZeneca PLC | $195.15 | +6.14% | $302.65B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GILD's Key Strengths?
- Strong portfolio of HIV/AIDS therapies.
- Established presence in liver disease treatment.
- Expanding oncology business through Kite Pharma acquisition.
- Robust pipeline of new drug candidates.
What Are GILD's Weaknesses?
- Reliance on a few key products for revenue.
- Patent expirations on key drugs.
- Exposure to biosimilar competition.
- Dependence on collaborations for pipeline expansion.
What Could Drive GILD Stock Higher?
- Clinical trial results for new oncology drug candidates.
- Continued revenue growth from Biktarvy in HIV treatment.
- Expansion of cell therapy business through new indications for Yescarta and Tecartus.
- Regulatory approvals for new therapies in development.
- Strategic collaborations to expand pipeline and access new technologies.
What Are the Key Risks for GILD?
- Insider selling — insiders were net sellers of roughly $2.9M recently.
- Patent expirations on key drugs, leading to generic competition.
- Competition from other pharmaceutical companies in key therapeutic areas.
- Pricing pressures from government and payers.
- Clinical trial failures.
- Regulatory challenges.
What Are the Growth Opportunities for GILD?
- Growth opportunity 1: Expansion in Oncology: Gilead's acquisition of Kite Pharma provides a platform for growth in cell therapy. The market for cell therapies is projected to reach $51.2 billion by 2030, driven by advancements in personalized medicine and increasing prevalence of cancer. Gilead's Yescarta and Tecartus offer significant potential, with ongoing research exploring new indications and combinations. Success in oncology will diversify Gilead's revenue streams and reduce reliance on HIV therapies.
- Growth opportunity 2: Advancements in HIV Treatment: Gilead continues to innovate in HIV treatment, developing long-acting therapies and potential cures. The global HIV treatment market is expected to grow, driven by increasing access to treatment and prevention efforts. Gilead's Biktarvy remains a leading therapy, and the company is exploring new approaches, such as broadly neutralizing antibodies, to achieve long-term remission. These advancements could solidify Gilead's dominance in HIV care.
- Growth opportunity 3: Strategic Collaborations: Gilead's collaborations with companies like Arcus Biosciences and Merck & Co. provide access to novel technologies and drug candidates. These partnerships expand Gilead's pipeline and diversify its research efforts. By collaborating with innovative companies, Gilead can accelerate the development of new therapies and address unmet medical needs in various therapeutic areas. Successful collaborations can lead to significant revenue opportunities and strengthen Gilead's competitive position.
- Growth opportunity 4: Geographic Expansion: Gilead has the opportunity to expand its presence in emerging markets, where access to healthcare is increasing. These markets offer significant growth potential for Gilead's existing products and pipeline candidates. By establishing partnerships and distribution networks in these regions, Gilead can reach new patient populations and drive revenue growth. Successful geographic expansion requires navigating regulatory hurdles and adapting to local market conditions.
- Growth opportunity 5: Liver Disease Therapies: Gilead has a strong portfolio of therapies for liver diseases, including hepatitis B and hepatitis C. The market for liver disease treatments is expected to grow, driven by increasing prevalence of these conditions and advancements in diagnostic technologies. Gilead's Vemlidy and Epclusa offer effective treatment options, and the company is exploring new approaches to address unmet needs in liver disease management. Continued innovation in this area can drive revenue growth and solidify Gilead's position as a leader in liver disease therapies.
What Opportunities Does GILD Have?
- Expansion into new therapeutic areas, such as inflammation and immunology.
- Growth in emerging markets.
- Development of long-acting HIV therapies.
- Advancements in cell therapy for cancer treatment.
What Threats Does GILD Face?
- Competition from other pharmaceutical companies.
- Pricing pressures from government and payers.
- Regulatory challenges.
- Clinical trial failures.
What Are GILD's Competitive Advantages?
- Patent protection on key drugs provides exclusivity and pricing power.
- Strong brand recognition and reputation in HIV/AIDS treatment.
- Extensive distribution network and established relationships with healthcare providers.
- Expertise in drug development and regulatory affairs.
- Strategic collaborations that provide access to novel technologies.
What Does GILD Do?
Gilead Sciences, Inc. was founded in 1987 with a vision to advance the care of patients suffering from life-threatening diseases. Initially focused on antiviral medicines, Gilead achieved a breakthrough with Tamiflu, an influenza treatment. The company solidified its position in HIV/AIDS treatment with a series of innovative drugs, including Truvada, Atripla, and Biktarvy, transforming the landscape of HIV care. Gilead's portfolio extends to liver diseases, with treatments like Harvoni and Epclusa for hepatitis C, achieving high cure rates. Expanding into oncology, Gilead acquired Kite Pharma, adding cell therapies like Yescarta and Tecartus to its offerings. The company's global reach spans the United States, Europe, and other international markets. Gilead collaborates with various companies, including Arcus Biosciences and Merck & Co., to develop new therapies and expand its pipeline. Headquartered in Foster City, California, Gilead continues to focus on addressing unmet medical needs through scientific innovation and strategic partnerships.
What Products and Services Does GILD Offer?
- Develops and commercializes antiviral drugs for HIV/AIDS.
- Offers treatments for liver diseases, including hepatitis B and C.
- Provides cell therapies for certain types of cancer.
- Researches and develops new therapies for life-threatening diseases.
- Collaborates with other companies to expand its pipeline.
- Markets its products globally, including in the United States and Europe.
- Focuses on areas of unmet medical need.
How Does GILD Make Money?
- Develops and patents pharmaceutical products.
- Conducts clinical trials to demonstrate safety and efficacy.
- Obtains regulatory approvals from agencies like the FDA.
- Manufactures and distributes its products globally.
- Generates revenue through sales of its patented drugs.
What Industry Does GILD Operate In?
Gilead Sciences operates in the highly competitive drug manufacturing industry, characterized by intense research and development, stringent regulatory requirements, and patent protection. The industry is driven by innovation, with companies constantly seeking to develop new therapies for unmet medical needs. Gilead competes with major pharmaceutical companies like MRK: Merck & Co., Inc. and PFE: Pfizer Inc. The market is influenced by factors such as aging populations, increasing healthcare spending, and advancements in biotechnology. Gilead's focus on antiviral therapies and oncology positions it to capitalize on these trends.
Who Are GILD's Key Customers?
- Patients with HIV/AIDS.
- Patients with liver diseases, such as hepatitis B and C.
- Patients with certain types of cancer.
- Hospitals and clinics that administer Gilead's therapies.
- Government healthcare programs that reimburse for Gilead's products.
Company Profile
Gilead Sciences, Inc. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Foster City, US. The company is led by CEO Daniel O'Day. GILD has traded publicly since 1992.
How Gilead Sciences, Inc. Is Valued
Gilead Sciences, Inc. carries a market capitalization of $162.98B, placing it in the large-cap category. Relative to its peer group, GILD's quantitative score of 94/100 is above the peer average of 70/100.
ROE 42%Key Financial Metrics
Return on equity for Gilead Sciences, Inc. stands at 42.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 16.4%, showing how much profit it generates from its asset base. GILD trades at a trailing price-to-earnings ratio of 16.91, below the Healthcare sector average of ~23x. Its free cash flow yield is 6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.97 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 9/9Financial Health
Gilead Sciences, Inc.'s Piotroski F-Score is 9/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 4.71 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Gilead Sciences, Inc. revenue of about $30.45B for fiscal 2026, with EPS near $-0.80. The estimate reflects 17 contributing analysts.
Net sellingInsider Activity
Over the past six months, Gilead Sciences, Inc. insiders filed 15 SEC Form 4 transactions — 12 sales and 3 purchases. On net that is roughly 23K shares disposed (about $2.9M), a signal worth weighing alongside the fundamentals.
GILD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Gilead's future, indicating that leadership sees potential for growth.
- Community sentiment has shifted positively, with discussions highlighting the company's strong pipeline in HIV and oncology.
- Recent partnerships and collaborations have bolstered Gilead's reputation, enhancing its market position and innovation potential.
- Increased focus on expanding access to treatments is resonating well with investors, reflecting a commitment to social responsibility.
Bear Case
- Concerns over patent expirations for key drugs have surfaced, which could impact future revenue streams.
- Market sentiment remains cautious due to ongoing competition in the biotech space, particularly from emerging therapies.
- Some community members express skepticism about Gilead's ability to sustain growth without breakthrough products in the near term.
- Recent earnings reports have shown mixed results, leading to uncertainty about the company's ability to meet investor expectations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
From the Earnings Call
“Our HIV business grew 10% year-over-year, reflecting 7% growth for Biktarvy and an impressive 87% growth for our U.S. PrEP business. The ongoing success of Yeztugo launch is a key driver of this growth in HIV prevention with first quarter sales growing 72% sequentially.”
— Daniel O'Day, Chairman and Chief Executive Officer
“Upfront IPR&D of $11.5 billion together with transaction financing expenses, collectively amounting to $9.50 per share are reflected in our updated EPS guidance. We are pleased to note that excluding these transaction-related costs, we are effectively maintaining our start of the year non-GAAP EPS guidance, highlighting the flexibility in our operating model and our agility as we flex to accommodate the needs of the…”
— Andrew Dickinson, Chief Financial Officer
GILD Q1 FY2026 earnings call transcript · 2026-05-07
GILD Latest News
-
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
benzinga · Jul 3, 2026
-
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
zacks.com · Jul 2, 2026
-
The FDA Just Approved a KEYTRUDA Combination That Could Become the Standard First-Line Treatment for Aggressive Breast Cancer
Insider Monkey · Jul 1, 2026
-
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
Yahoo! Finance: GILD News · Jul 1, 2026
GILD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GILD.
Price Targets
Consensus target: $155.41
GILD MoonshotScore
What does this score mean?
The MoonshotScore rates GILD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
The FDA Just Approved a KEYTRUDA Combination That Could Become the Standard First-Line Treatment for Aggressive Breast Cancer
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
Latest Gilead Sciences, Inc. Analysis
AI Sector Faces Headwinds as Nasdaq Dips 1.61%, Micron Plunges 5.49%
2 min readNasdaq Retreats 1.61% While GILD Jumps 4.21% Amid Mixed Market Session
2 min readRocket Lab Gains 1.96% on New Launch Contracts
2 min readCREG Skyrockets 85.41% in Pre-Market Trading Amid Industrials Sector Movement
3 min readBitcoin Holds Near $72750 Amid Regulatory Uncertainty
3 min readLeadership: Daniel O'Day
Chairman and Chief Executive Officer
Daniel O'Day has served as the Chairman and Chief Executive Officer of Gilead Sciences since March 2019. Prior to joining Gilead, he spent over 30 years at Roche, where he held various leadership positions, including Chief Operating Officer of Roche Pharmaceuticals. He has extensive experience in the pharmaceutical industry, with a focus on commercial operations, product development, and strategic planning. O'Day holds a Bachelor of Science degree in Biology from Georgetown University.
Track Record: Since becoming CEO of Gilead, Daniel O'Day has overseen the acquisition of Kite Pharma and the expansion of Gilead's oncology business. He has also led the company's response to the COVID-19 pandemic, with Veklury becoming a key treatment. Under his leadership, Gilead has focused on diversifying its pipeline and expanding its presence in new therapeutic areas. O'Day has emphasized innovation and collaboration as key drivers of Gilead's growth.
Common Questions About GILD (Healthcare)
What does Gilead Sciences, Inc. do?
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines to address unmet medical needs. The company's primary focus is on antiviral therapies, particularly for HIV/AIDS and liver diseases. Gilead's portfolio includes blockbuster drugs like Biktarvy for HIV and Epclusa for hepatitis C. The company has also expanded into oncology through the acquisition of Kite Pharma, offering cell therapies for certain types of cancer. Gilead operates globally, marketing its products in the United States, Europe, and other international markets. The company invests heavily in research and development to discover new therapies and improve existing treatments.
What do analysts say about GILD stock?
Analyst consensus on Gilead Sciences, Inc. is mixed, with opinions varying based on the company's pipeline progress, patent expirations, and competition. Key valuation metrics, such as the P/E ratio of 16.9, are considered in relation to Gilead's growth prospects. Some analysts highlight the potential for growth in oncology and HIV treatment, while others express concern about the impact of generic competition on key drugs. Investors should conduct their own research and consider their individual risk tolerance before making investment decisions.
What are the main risks for GILD?
Gilead Sciences, Inc. faces several key risks, including patent expirations on key drugs, which could lead to generic competition and reduced revenue. The company also faces competition from other pharmaceutical companies in key therapeutic areas, such as HIV and oncology. Pricing pressures from government and payers could also impact Gilead's profitability. Clinical trial failures represent another risk, as the company relies on the successful development of new therapies to drive future growth. Regulatory challenges and changes in healthcare policy could also impact Gilead's business.
What are the key factors to evaluate for GILD?
Gilead Sciences, Inc. (GILD) holds an AI score of 94/100 (high). P/E: 16.9x vs the S&P 500's ~20-25x. Analysts target $155.41 (+18%). Not financial advice.
How frequently does GILD data refresh on this page?
GILD prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GILD's recent stock price performance?
Gilead Sciences, Inc. (GILD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong portfolio of HIV/AIDS therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GILD overvalued or undervalued right now?
Gilead Sciences, Inc. (GILD) trades at 16.9x earnings. Analysts target $155.41 (+18%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GILD?
Before investing in Gilead Sciences, Inc. (GILD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial circumstances.